Investigative Sites

Tufts CSDD survey finds fostering healthy relationships with site staff is key to a positive outlook.

Webinar Date/Time: Wednesday, March 29, 2023 at 11am ET |10 am CT | 8am PT

Webinar Date/Time: Thu, Mar 16, 2023 11:00 AM EDT

Kroger Health, the healthcare division of The Kroger Co., has established its clinical trial site network in conjunction with Kroger's first trial in active recruitment for colorectal cancer gut and immune health observation.

Webinar Date/Time: Mon, Feb 13, 2023 10:00 AM EST

Webinar Date/Time: Wed, Nov 30, 2022 10:00 AM EST

Dr. Pratik Darji, Head of Progressive Clinical Research Solutions in Gujarat, India discusses the state of clinical trials in the country.

A more crowded space is presenting new challenges for stakeholders that must be addressed to improve efficiency.

Sites not expected to fade away even as DCTs continue to grow past COVID-19.

Helping physicians and patients discuss local trials at the point of care.

Sponsors and CROs can ease the burdens of patients, sites, and physicians by identifying these 3 key areas.

2020 Tufts CSDD study examines relationship between investigative site personnel diversity and study participant diversity.

Aasma Shaukat, MD, MPH, study co-lead, professor of medicine, and director of outcomes research for the Division of Gastroenterology and Hepatology at New York University Langone Health discusses how sites have evolved since COVID-19.

Industry must act now to minimize effects of COVID-19 on clinical research.

In new age of digital, investigators must carefully create strategies to keep engagement high.

A win-win-win for sites, sponsors, and referral partners.

2021 survey highlights challenges and opportunities for investigators, coordinators, and patients.

New benchmarks uncover a maturing and globally-shifting market.

Mary Costello, Head of Site and Investigator Networks at Medable, and Stephanie Abbott, Clinical Research Director at Western Washington Medical Group, discuss the changing landscape of decentralized clinical trials.

Has technology taken the industry too far?

New support models range from flexible software platforms, IROs, and DROs.

InterveXion CEO Keith Ward and Andrew Schafer, vice president of strategy for Biospatial discuss the details of a study which utilizes EMS data to identify sites for a Phase II clinical trial.

Industry-wide unity paves path for preparedness.

Bringing clinical trials to patients’ homes can address existing site-based challenges.

Lessons learned during the pandemic from University of Louisville.

While it's important to note that there are areas where the industry can improve, there are unique opportunities of improvement for specific types of sites and the number of studies conducted there.

Building authentic trust lays at the heart of creating more patient-centric trials.

Comparing late-stage COVID-19 vaccine trials to historical practices.

Findings from a Tufts study examining the effects of COVID-19 on clinical trials.